Addex Therapeutics Ltd. (fka ADDXF)

[tykundegex]

Previously confidential but newly published white paper on Addex's ADX48621 (for Parkinson's Disease) shows the market & revenue potential!

http://www.addexpharma.com/fileadmin/user_upload/IR_Presentations/2012/Dipraglurant_IR_in_PD_and_beyond_22_Dec_2011_final_01.pdf

"The combined peak U.S. annual sales potential (excluding disease modification) for the PD indications alone is estimated to be in the range of $1.8bn to $2.7bn , (source Michael J Fox Foundation 2011)."

If the clinical results are good (due end March), Addex is in a great position as this particular modulator is wholly owned by them (no partner, just a $900k grant from the Michael J. Fox foundation).

With the ADX71149 they negotiated a "low double digit %" royalty fee with Janssen but early on... so they should be able to do even better with ADX48621 if it's proven!

From here (PPS today @ CHF 6.40) we could be looking at a 10x jump in a matter of months -- if the results are good and they announce a partnership soon thereafter.

Of course, the last time we expected good news from a Phase II Clinical trial, it was found their drug caused liver damage and the shares plummeted 80%. Nonetheless, the PPS is lower today than post-plummet, and even with bad news the company valuation is very attractive given their unique allosteric R&D platform and pipeline of candidate modulators.